A detailed history of Clough Capital Partners L P transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Clough Capital Partners L P holds 6,300 shares of GILD stock, worth $591,885. This represents 0.06% of its overall portfolio holdings.

Number of Shares
6,300
Previous 6,300 -0.0%
Holding current value
$591,885
Previous $432,000 22.22%
% of portfolio
0.06%
Previous 0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $102,578 - $116,326
-1,400 Reduced 18.18%
6,300 $510,000
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $479,864 - $688,919
7,700 New
7,700 $661,000
Q3 2020

Nov 17, 2020

SELL
$62.1 - $78.08 $6.41 Million - $8.06 Million
-103,200 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $6.06 Million - $7.04 Million
-83,800 Reduced 44.81%
103,200 $7.94 Million
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $11.7 Million - $15 Million
187,000 New
187,000 $14 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Clough Capital Partners L P Portfolio

Follow Clough Capital Partners L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

News

Stay updated on Clough Capital Partners L P with notifications on news.